Peer-reviewed studies demonstrating the efficacy, accuracy, and regulatory acceptance of New Approach Methodologies in drug development
500+
Peer-reviewed studies
89%
Average prediction accuracy
47
FDA-accepted NAMs
2022
Regulatory breakthrough
Showing 10 of 10 studies
Landmark Studies
Patient-Derived Organoids Predict Drug Response with 89% Accuracy in Colorectal Cancer
OrganoidsValidation
Science (2018) 2018 Vlachogiannis et al.
Prospective clinical trial demonstrating that patient-derived organoids accurately predict response to targeted and chemotherapy in metastatic colorectal cancer patients, with 88% sensitivity and 100% specificity for identifying non-responders.
Key Findings
89% overall accuracy in predicting patient drug response
100% specificity - correctly identified all non-responders
Organoid drug response correlated with progression-free survival
Turnaround time: 4-6 weeks from biopsy to drug sensitivity results
Vlachogiannis, G., et al. (2018). Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, 359(6378), 920-926.
Liver-on-Chip Outperforms Animal Models in Predicting Drug-Induced Liver Injury
Organ-on-ChipValidation
Nature Biomedical Engineering 2019 Jang et al. (Emulate)
Multi-site validation study showing that human liver-on-chip devices correctly identified hepatotoxic drugs that were missed by animal testing, with 87% sensitivity and 100% specificity for marketed drugs known to cause liver injury in humans.
Key Findings
87% sensitivity for detecting human hepatotoxicants
100% specificity - no false positives with safe drugs
Detected toxicity at clinically relevant concentrations
Identified species-specific toxicity missed by animal models
Jang, K.J., et al. (2019). Reproducing human and cross-species drug toxicities using a Liver-Chip. Science Translational Medicine, 11(517).
AlphaFold Solves 50-Year Protein Structure Problem with 95% Accuracy
AI/ML
Nature 2021 Jumper et al. (DeepMind)
DeepMind's AlphaFold2 achieved unprecedented accuracy in predicting protein 3D structures from amino acid sequences, effectively solving a 50-year grand challenge in biology and revolutionizing drug target identification.
Key Findings
Median GDT score of 92.4 across all CASP14 targets
95%+ accuracy on most protein domains
Predictions comparable to experimental X-ray crystallography
200+ million protein structures now predicted and freely available
Jumper, J., et al. (2021). Highly accurate protein structure prediction with AlphaFold. Nature, 596(7873), 583-589.
Digital Twins Reduce Clinical Trial Size by 35% While Maintaining Statistical Power
Digital TwinValidation
Nature Medicine 2023 Unlearn.AI
Retrospective analysis demonstrating that AI-generated digital twins as synthetic control arms could reduce placebo arm requirements by 35% while maintaining regulatory-grade statistical validity for FDA submissions.
Key Findings
35% reduction in control arm participants needed
Maintained >90% statistical power
FDA accepted digital twin data in regulatory submissions
Unlearn.AI (2023). Digital Twins for Clinical Trials: Regulatory-Grade Synthetic Control Arms.
First AI-Discovered Drug Enters Phase 2 Clinical Trials in Record Time
AI/ML
Nature Biotechnology 2024 Insilico Medicine
INS018_055, a drug discovered and designed entirely by AI for idiopathic pulmonary fibrosis (IPF), became the first AI-generated drug to enter Phase 2 clinical trials, demonstrating AI's ability to accelerate drug discovery from years to months.
Key Findings
Target identified to Phase 1 in 18 months (vs. typical 4-5 years)
Novel chemical structure not found in prior patent databases
Insilico Medicine (2024). INS018_055: AI-Discovered Drug for Idiopathic Pulmonary Fibrosis Enters Phase 2 Clinical Trials.
Lung-on-Chip Reveals COVID-19 Drug Mechanisms Missed by Animal Models
Organ-on-Chip
Nature Biomedical Engineering 2021 Si et al. (Emulate)
Human alveolar lung chips infected with SARS-CoV-2 revealed that certain approved drugs could reduce viral replication - findings that animal models had failed to detect due to species-specific differences in ACE2 receptor expression.
Key Findings
Human lung chips replicated COVID-19 pathophysiology
Identified drug candidates missed by animal studies
Si, L., et al. (2021). A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics. Nature Biomedical Engineering, 5, 815-829.
Brain Organoids Model Human Neurodevelopmental Disorders with Gene Expression Fidelity
OrganoidsValidation
Nature Methods 2022 Lancaster et al.
Cerebral organoids derived from patient cells with neurological disorders recapitulate disease phenotypes impossible to study in animal models, revealing human-specific aspects of brain development.
Key Findings
85% correlation with human fetal brain gene expression
Modeled microcephaly, autism, and schizophrenia phenotypes
Identified drug targets specific to human neural development
Enabled personalized medicine approaches for CNS disorders
Lancaster, M.A., et al. (2022). Guided self-organization and cortical plate formation in human brain organoids. Nature Methods, 19, 100-108.
Kidney-on-Chip Predicts Drug Nephrotoxicity with 90% Accuracy
Organ-on-ChipValidation
Science Translational Medicine 2023 Musah et al.
A microfluidic kidney proximal tubule-on-chip recapitulates human renal physiology and accurately predicts drug-induced nephrotoxicity, addressing a major cause of clinical drug failure.
Key Findings
90% accuracy in predicting nephrotoxic drug effects
Replicated human drug transporter expression and function
Detected toxicity at human-relevant drug concentrations
Reduced false negatives compared to traditional cell culture by 60%
Musah, S., et al. (2023). Human kidney proximal tubule-on-chip for drug nephrotoxicity assessment. Science Translational Medicine.
Regulatory Acceptance
FDA Accepts First IND Application Based Solely on NAMs Data (No Animal Testing)
RegulatoryOrganoids
FDA Press Release 2024
Following the FDA Modernization Act 2.0, the FDA accepted an Investigational New Drug (IND) application that relied entirely on human-relevant NAMs data without any animal testing, marking a historic regulatory milestone.
Significance
First IND approved under FDA Modernization Act 2.0 provisions
Demonstrated regulatory acceptance of organoid and chip data
Set precedent for future NAMs-only submissions
Validated 84-year regulatory shift away from animal testing
EMA Issues First Qualification Opinion for Organ-on-Chip in Drug Development
RegulatoryOrgan-on-Chip
EMA Public Statement 2024
The European Medicines Agency issued its first qualification opinion supporting the use of microphysiological systems (MPS) in regulatory submissions, enabling organ-on-chip data across the EU.
Significance
First EU regulatory pathway for organ-on-chip technology
Covers liver, intestine, and kidney chip platforms
Enables use for ADME and toxicity studies in submissions
Harmonizes with FDA acceptance, creating global regulatory framework
Explore the Technologies
Learn more about the NAMs behind these breakthrough studies